Semagacestat (LY-450139; LY-4501)

Alias: Semagacestat; LY450139; LY 4501; LY 450139; LY-450139; LY4501; LY-4501
Cat No.:V0716 Purity: ≥98%
Semagacestat (also known as LY450139; LY4501) is a novel and potent γ-secretase inhibitor/blocker for Aβ42, Aβ40 and Aβ38 with the potential for treating Alzheimer's disease.
Semagacestat (LY-450139; LY-4501) Chemical Structure CAS No.: 425386-60-3
Product category: Gamma-secretase
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
1mg
5mg
10mg
25mg
50mg
100mg
250mg
Other Sizes
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text

 

  • Business Relationship with 5000+ Clients Globally
  • Major Universities, Research Institutions, Biotech & Pharma
  • Citations by Top Journals: Nature, Cell, Science, etc.
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

Semagacestat (also known as LY450139; LY4501) is a novel and potent γ-secretase inhibitor/blocker for Aβ42, Aβ40 and Aβ38 with the potential for treating Alzheimer's disease. In H4 human glioma cells, it inhibits Aβ42, Aβ40, and Aβ38 with IC50 values of 10.9 nM, 12.1 nM, and 12.0 nM.In addition, it inhibits Notch signaling with an IC50 of 14.1 nM. Due to a lackluster performance, semagacestat's Phase III trials were stopped in August 2010.

Biological Activity I Assay Protocols (From Reference)
Targets
Aβ42 (IC50 = 10.9 nM); Aβ38 (IC50 = 12 nM); Aβ40 (IC50 = 12.1 nM); Notch (IC50 = 14.1 nM)
ln Vitro
Semagacestat diminishes the amount of Aβ42, Aβ40, and Aβ38 secreted by H4 human glioma cells that persistently overexpress human wild-type APP into the culture medium (IC50 values of 10.9 nM, 12.1 nM, and 12.0 nM, respectively), all without impairing cell viability. Additionally, at high concentrations, semagacestat unexpectedly attenuates the increase in β-CTF in cell lysates, which has an ECmax of 16.0 nM. Semagacestat exhibits minimal selectivity in preserving Notch signaling, with Notch IC50/Aβ42 IC50 of only 1.3, and inhibits Notch signaling with an IC50 of 14.1 nM.[1] Semagacestat causes a concentration-dependent decrease in the amount of Aβ40 secreted into the medium, with an IC50 of 111 nM from murine CTX that expresses endogenous murine APP; however, based on data from neurons from wild type mice, the amount of murine Aβ42 formed in CTX is approximately 12-fold less than that of Aβ40.[2]
ln Vivo
Using the Y-maze task, oral administration of Semagacestat (1 mg/kg) to 5.5-month-old APP-transgenic Tg2576 mice significantly improves memory deficits on spatial working memory. These effects vanish after 8 days of subchronic dosing. While LY450139 increases β-CTF at 0.3-10 mg/kg and decreases hippocampal levels of both Aβ42 and Aβ40 at 10 mg/kg (22-23% reduction) and 30 mg/kg (36-41% reduction), it does so in a dose-dependent manner with no inhibition on the processing of other γ-secretase substrates in the brain, such as Notch, N-cadherin, or EphA4. However, it impairs normal cognition in wild-type mice and 3-month-old Tg2576 mice, failing to restore cognitive deficits in the Y-maze test.[1]
Enzyme Assay
Semagacestat is administered to H4 human glioma cells that are stable overexpressors of human wild-type APP695 for a duration of 24 hours at different concentrations. Using different ELISA kits, the levels of Aβ42, Aβ40, and Aβ38 in the media are measured. The constitutively active form of Notch (NotchΔE) expression vector is constructed into a pcDNA3.1 vector with a sequence modification from mouse to human, encoding bases 1-60 and 5193-6657 of the human Notch1 coding region (NM_017617). The Cignal RBP-Jk Reporter Assay Kit is used to assess notch signaling activity. The Notch intracellular domain produced by γ-secretase activates the transcription factor RBP-Jk protein [CSL/CBF1/Su(H)/Lag1]. The RBP-Jk-responsive luciferase construct and the human NotchΔE expression vector are transiently transfected into H4 cells using Lipofectamine 2000. The cells are then exposed to different concentrations of Semagacestat for a duration of 16 hours. The Dual-Glo Luciferase Assay System gauges notch signaling by measuring luciferase activity in the cell lysate.
Cell Assay
Semagacestat is used to incubate cells for a full day. The ability of the cells to decrease 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) after being incubated with 0.5 mg/mL MTT for 60 minutes is used to determine the viability of the cells. Cells are digested and subjected to western blotting analysis in order to identify sAPP species.
Animal Protocol
Mice: The Swedish mutation (K670N/M671L) in female Tg2576 mice expressing human APP695 is employed. It is necessary to obtain male transgenic mice and breed them with female B6SJLF1/J mice. Four distinct experiments are carried out to determine the effects of drugs on cognitive function. Experiment 1's goal is to clarify how acute and subchronic medication effects affect Tg2576 mice's cognitive deficits. Tg2576 mice, aged 5.5 months, are given oral doses of Semagacestat, BMS-708163, and GSM-2 for a duration of 8 days. Three hours after administration on days 1 and 8, Y-maze tests are used to assess spatial working memory. In the Y-maze test, vehicle-treated Tg2576 mice exhibit noticeably lower spontaneous alternation rates than WT mice, indicating impairments in spatial working memory. Acute effects of 1 mg/kg Semagacestat, 1 mg/kg BMS-708163, and 0.1–0.3 mg/kg GSM-2 are shown to significantly improve cognitive deficits on day 1. However, the GSI effects end on day 8, while the significant effects of GSM-2 (subchronic effects) are still present. On day 8, after the Y-maze test, mice are immediately killed so that ELISA can be used to measure the levels of Aβ42, Aβ40, and β-CTF in their hippocampi.
References

[1]. J Neurosci . 2012 Feb 8;32(6):2037-50.

[2]. J Neurochem . 2009 Sep;110(5):1377-87.

These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C19H27N3O4
Molecular Weight
361.44
Exact Mass
361.20
Elemental Analysis
C, 63.14; H, 7.53; N, 11.63; O, 17.71
CAS #
425386-60-3
Appearance
Solid powder
SMILES
C[C@@H](C(=O)N[C@H]1C2=CC=CC=C2CCN(C1=O)C)NC(=O)[C@H](C(C)C)O
InChi Key
PKXWXXPNHIWQHW-RCBQFDQVSA-N
InChi Code
InChI=1S/C19H27N3O4/c1-11(2)16(23)18(25)20-12(3)17(24)21-15-14-8-6-5-7-13(14)9-10-22(4)19(15)26/h5-8,11-12,15-16,23H,9-10H2,1-4H3,(H,20,25)(H,21,24)/t12-,15-,16-/m0/s1
Chemical Name
(2S)-2-hydroxy-3-methyl-N-[(2S)-1-[[(5S)-3-methyl-4-oxo-2,5-dihydro-1H-3-benzazepin-5-yl]amino]-1-oxopropan-2-yl]butanamide
Synonyms
Semagacestat; LY450139; LY 4501; LY 450139; LY-450139; LY4501; LY-4501
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: ~72 mg/mL (~199.2 mM)
Water: <1 mg/mL
Ethanol: ~41 mg/mL (~113.4 mM)
Solubility (In Vivo)
0.5% methylcellulose: 30 mg/mL
 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.7667 mL 13.8336 mL 27.6671 mL
5 mM 0.5533 mL 2.7667 mL 5.5334 mL
10 mM 0.2767 mL 1.3834 mL 2.7667 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01035138 Completed Drug: semagacestat Alzheimer's Disease Eli Lilly and Company December 2009 Phase 3
Biological Data
  • Semagacestat (LY450139)
  • Semagacestat (LY450139)
  • Semagacestat (LY450139)
    Drug effects on APP processing and Notch signaling in cells.J Neurosci.2012 Feb 8;32(6):2037-50.
  • Semagacestat (LY450139)
    Acute and subchronic drug effects on cognitive deficits in Tg2576 mice (Experiment 1).J Neurosci.2012 Feb 8;32(6):2037-50.
  • Semagacestat (LY450139)
    Subchronic drug effects on cognitive deficits in Tg2576 mice at high doses that robustly reduce hippocampal Aβ levels (Experiment 2).J Neurosci.2012 Feb 8;32(6):2037-50.
  • Semagacestat (LY450139)
    Acute and subchronic drug effects on normal cognitive function in WT mice (Experiment 4).J Neurosci.2012 Feb 8;32(6):2037-50.
  • Semagacestat (LY450139)
    Localized accumulation of human β-CTF in Tg2576 mouse hippocampus following GSI treatment.J Neurosci.2012 Feb 8;32(6):2037-50.
  • Semagacestat (LY450139)
    Localized accumulation of APP-CTFs in Tg2576 mouse hippocampus following GSI treatment.J Neurosci.2012 Feb 8;32(6):2037-50.
  • Semagacestat (LY450139)
    Localized accumulation of mouse endogenous APP-CTFs in WT mouse hippocampus following GSI treatment.J Neurosci.2012 Feb 8;32(6):2037-50.
Contact Us